Ms. Carolyn Bonner reports

MEDICUS PHARMA LTD. ANNOUNCES APPOINTMENT OF HUMA QAMAR, MD AS CHIEF SCIENTIFIC OFFICER & HEAD OF R&D PROGRAM

Medicus Pharma Ltd. has appointed of Huma Qamar, MD, as the chief scientific officer, and head of the research and development (R&D) program.

Dr. Qamar has worked in the clinical research field for some of the most renowned Ivy league institutions, such as Yale University, Harvard University and the University of Pennsylvania. She has robust experience in developing phase 1 to 4 clinical protocols and execution of clinical studies, FDA (Food and Drug Administration) inspections, billing and compliance audits, and medical affairs team management. She has expertise in multiple therapeutic areas, including oncology (Heme-Onc, CAR-T, rare tumours, sarcoma, melanoma, women's health, GU (genitourinary) and GI (gastrointestinal), and fetal oncology), gene therapy, vaccines, rheumatology, dermatology, neurology, cardiology, hepatology and infectious diseases. Dr. Qamar was most recently serving as the head of clinical development and clinical operations at Ocugen Inc.

"We are thrilled to welcome Dr. Qamar to lead our R&D program," stated Dr. Raza Bokhari, executive chairman and chief executive officer. "Huma is a trusted and a respected leader in the industry, well liked by her peers and superiors, and is well known for her laser-sharp focus and sense of urgency to deliver measurable results in drug development."

The company also announced election of James P. Quinlan, Medicus chief financial officer, as chairman of the board of Skinject Inc., the wholly owned subsidiary of Medicus, along with Dr. Edward J. Brennan, the chief medical officer of the company, and Carolyn Bonner, the president of company, as members of the Skinject board of directors.

About Medicus Pharma Ltd.

Medicus Pharma is a clinical-stage, multistrategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials.

Through its diverse experience and extensive industry network, the company is building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes, and alleviating pain and suffering. Utilizing a thesis-driven collaborative process, Medicus identifies, acquires and advances relatively derisked clinical-stage assets through clinical development and commercialization.

Skinject Inc., a wholly owned subsidiary of Medicus Pharma, is a development-stage life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumour cells. The company currently has an FDA-approved phase 2 trial actively recruiting patients.

We seek Safe Harbor.